StockDrifts LogoStockDrifts

Myeongmun Pharmaceutical 017180

Company
명문제약Myeongmun Pharmaceutical
Insiders
7
Buys
58
Total Value
₩884M ($614K)
Avg Return
+10.11%
Last Filing
2026-07-01

Myeongmun Pharmaceutical (017180) has 58 disclosed insider purchases and 0 disclosed disposals on record, filed by 7 distinct insiders. Together those filings cover ₩884M ($614K) in reported transaction value. The earliest filing StockDrifts holds for Myeongmun Pharmaceutical is dated 2023-07-13; the most recent is 2026-07-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +10.11%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-11BUYMarket Buy
임기섭
Lim Lim Seop
moving3.6K₩1,253+0.2%₩5M ($3K)
2026-08-04BUYMarket Buy
양환태
Hwantae Yang
Managing Director44₩1,136+1.9%₩50K ($35)
2026-08-03BUYMarket Buy
권용진
Yongjin Kwon
moving2.5K₩1,083+6.9%₩3M ($2K)
2026-08-03BUYMarket Buy
양환태
Hwantae Yang
Managing Director2.7K₩1,083+6.9%₩3M ($2K)
2026-07-01SELL증여
정준일
Jeong Jun-il
Managing Director-119.0K₩1,282+1.0%₩153M ($106K)
2026-07-01BUYMarket Buy
임기섭
Lim Lim Seop
moving3.5K₩1,282-1.0%₩4M ($3K)
2026-06-30BUYMarket Buy
임기섭
Lim Lim Seop
moving1.4K₩1,272-0.2%₩2M ($1K)
2026-06-29BUYMarket Buy
임기섭
Lim Lim Seop
moving3.6K₩1,270-0.1%₩5M ($3K)
2026-06-11BUYMarket Buy
양환태
Hwantae Yang
Managing Director5.4K---
2026-04-28BUY자사주상여금
유정권
Yoo Jeong-kwon
Managing Director2.7K₩1,756+1.8%₩5M ($3K)
2026-04-28BUY자사주상여금
장윤수
Jang Yunsu
Managing Director7.4K₩1,756+1.8%₩13M ($9K)
2026-04-28BUY자사주상여금
이장호
Jangho Lee
Managing Director2.7K₩1,756+1.8%₩5M ($3K)
2026-04-28BUY자사주상여금
임기섭
Lim Lim Seop
moving2.5K₩1,756+1.8%₩4M ($3K)
2026-04-28BUY자사주상여금
이경희
Kyunghee Lee
moving2.5K₩1,756+1.8%₩4M ($3K)
2026-04-28BUY자사주상여금
양환태
Hwantae Yang
moving2.7K₩1,756+1.8%₩5M ($3K)
2026-04-28BUY자사주상여금
권용진
Yongjin Kwon
moving2.5K₩1,756+1.8%₩4M ($3K)
2026-04-28BUY자사주상여금
이영미
Youngmi Lee
Managing Director2.8K₩1,756+1.8%₩5M ($3K)
2026-02-10BUYMarket Buy
임기섭
Lim Lim Seop
moving1.7K₩1,817+6.4%₩3M ($2K)
2026-02-05BUYMarket Buy
임기섭
Lim Lim Seop
moving1.7K₩1,791+7.9%₩3M ($2K)
2026-02-04BUYMarket Buy
임기섭
Lim Lim Seop
moving4.6K₩1,761+9.8%₩8M ($6K)
2026-02-03BUYMarket Buy
임기섭
Lim Lim Seop
moving12.8K₩1,777+8.8%₩23M ($16K)
2026-02-02BUYMarket Buy
임기섭
Lim Lim Seop
moving2.2K₩1,731+11.7%₩4M ($3K)
2026-01-30BUYMarket Buy
임기섭
Lim Lim Seop
moving5.0K₩1,790+8.0%₩9M ($6K)
2026-01-08BUYMarket Buy
이경희
Kyunghee Lee
moving10.0K₩1,810+6.8%₩18M ($13K)
2026-01-06BUYMarket Buy
정준일
Jeong Jun-il
Managing Director9.0K₩1,796+7.6%₩16M ($11K)
2025-12-24BUYMarket Buy
이경희
Kyunghee Lee
moving28.2K₩1,823+6.0%₩51M ($36K)
2025-12-24BUYMarket Buy
정준일
Jeong Jun-il
Managing Director4.5K₩1,823+6.0%₩8M ($6K)
2025-12-23BUYMarket Buy
정준일
Jeong Jun-il
Managing Director5.5K₩1,850+4.5%₩10M ($7K)
2025-12-23BUYMarket Buy
이경희
Kyunghee Lee
moving8.8K₩1,850+4.5%₩16M ($11K)
2025-12-18BUYMarket Buy
임기섭
Lim Lim Seop
moving5.5K₩1,850+4.5%₩10M ($7K)
2025-12-17BUYMarket Buy
임기섭
Lim Lim Seop
moving4₩1,945-0.6%₩8K ($5)
2025-12-15BUYMarket Buy
임기섭
Lim Lim Seop
moving10.6K₩1,826+5.9%₩19M ($13K)
2025-12-11BUYMarket Buy
정준일
Jeong Jun-il
Managing Director10.0K₩1,887+2.4%₩19M ($13K)
2025-12-10BUYMarket Buy
정준일
Jeong Jun-il
Managing Director10.1K₩1,800+7.4%₩18M ($13K)
2025-12-09BUYMarket Buy
정준일
Jeong Jun-il
Managing Director39.9K₩1,827+5.8%₩73M ($51K)
2025-12-08BUYMarket Buy
정준일
Jeong Jun-il
Managing Director10.0K₩1,820+6.2%₩18M ($13K)
2025-12-04BUYMarket Buy
정준일
Jeong Jun-il
Managing Director9.0K₩1,705+13.4%₩15M ($11K)
2025-12-03BUYMarket Buy
정준일
Jeong Jun-il
Managing Director14.0K₩1,706+13.3%₩24M ($17K)
2025-12-02BUYMarket Buy
정준일
Jeong Jun-il
Managing Director3.0K₩1,709+13.1%₩5M ($4K)
2025-12-02BUYMarket Buy
이경희
Kyunghee Lee
moving7.9K₩1,709+13.1%₩14M ($9K)
2025-12-01BUYMarket Buy
정준일
Jeong Jun-il
Managing Director3.0K₩1,712+12.9%₩5M ($4K)
2025-11-28BUYMarket Buy
정준일
Jeong Jun-il
Managing Director985₩1,712+12.9%₩2M ($1K)
2025-11-25BUYMarket Buy
임기섭
Lim Lim Seop
moving125₩1,709+13.1%₩214K ($148)
2025-11-24BUYMarket Buy
임기섭
Lim Lim Seop
moving2.7K₩1,735+11.4%₩5M ($3K)
2025-11-21BUYMarket Buy
임기섭
Lim Lim Seop
moving5.0K₩1,764+9.6%₩9M ($6K)
2025-11-20BUYMarket Buy
배철한
Bae Cheol-han
CEO/President17.2K₩1,782+8.5%₩31M ($21K)
2025-11-20BUYMarket Buy
임기섭
Lim Lim Seop
moving3.3K₩1,782+8.5%₩6M ($4K)
2025-11-19BUYMarket Buy
배철한
Bae Cheol-han
CEO/President20.0K₩1,758+9.9%₩35M ($24K)
2025-11-19BUYMarket Buy
임기섭
Lim Lim Seop
moving2.5K₩1,758+9.9%₩4M ($3K)
2025-11-18BUYMarket Buy
배철한
Bae Cheol-han
CEO/President20.0K₩1,731+11.7%₩35M ($24K)

Showing the 50 most recent of 71 filings.

Frequently asked questions

Who has been buying Myeongmun Pharmaceutical stock?
7 distinct insiders have filed 58 disclosed insider purchases in Myeongmun Pharmaceutical (017180), most recently on 2026-07-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Myeongmun Pharmaceutical have?
Myeongmun Pharmaceutical has 58 buy-side and 0 sell-side disclosures on record, covering ₩884M ($614K) in total reported value, spanning 2023-07-13 to 2026-07-01.
Where does StockDrifts get Myeongmun Pharmaceutical insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Myeongmun Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.